What's in CSL Behring's pipeline?

CSL Behring has 42 drugs in our index: 12 marketed, 0 filed, 12 in Phase 3, 10 in Phase 2, 7 in Phase 1.

Which companies overlap with CSL Behring's portfolio?

Top competitors by shared drug class: Baxalta now part of Shire, Grifols Therapeutics LLC, Alexion Pharmaceuticals, Inc., Bayer, Biotest.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/csl-behring.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

CSL Behring — Portfolio Competitive Intelligence Brief

CSL Behring pipeline: 12 marketed, 0 filed, 12 Phase 3, 10 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 12 Phase 3 10 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
CE1226	CE1226	marketed			Other
Voncento	Voncento	marketed			Other
IgPro10	IgPro10	marketed
Afstyla®	Afstyla®	marketed	Recombinant clotting factor VIII	Factor VIII (coagulation factor VIII)	Hematology
IgPro	IgPro	marketed	Intravenous immunoglobulin (IVIG)	Multiple pathogenic antigens (polyvalent)	Immunology
Blood coagulation Factor VIII and vWF, human	Blood coagulation Factor VIII and vWF, human	marketed
Haemocomplettan® P	Haemocomplettan® P	marketed	Prothrombin complex concentrate (PCC)	Clotting factors II, VII, IX, X	Hematology
Vivaglobin	Vivaglobin	marketed			Other
Hizentra	Hizentra	marketed			Other
Cryoprecipitate	Cryoprecipitate	marketed			Other
Filsuvez	garadacimab	marketed	Anti-Factor XIIa monoclonal antibody	Activated Factor XII (FXIIa)	Hematology
IgPro20	IgPro20	marketed	Immunoglobulin replacement therapy	Polyclonal IgG (multiple epitopes)	Immunology

Therapeutic area mix

Hematology · 8
Immunology · 8
Other · 6
Immunology / Rare disease · 1
Oncology · 1
Cardiovascular · 1
Pulmonology / Genetic / Rare Disease · 1
Hematology / Anticoagulation reversal · 1
Immunology / Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baxalta now part of Shire · 4 shared drug classes
Grifols Therapeutics LLC · 2 shared drug classes
Alexion Pharmaceuticals, Inc. · 2 shared drug classes
Bayer · 2 shared drug classes
Biotest · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
Aldeyra Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CSL Behring:

Cite this brief

Drug Landscape (2026). CSL Behring — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/csl-behring. Accessed 2026-05-13.